Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TET3 | O43151 | 1/20 | 0.43 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.43 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.43 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.43 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19469594 | 0.93 | MEN1 (0.52) | KMT2AMEN1TSHREPHX2AKR1C1 | |
| SCHEMBL25010550 | 0.85 | EPHX2 (0.45) | EPHX2SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL2534042 | 0.85 | OPRL1 (0.50) | EPHX2SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL31169150 | 0.84 | OPRL1 (0.42) | KMT2AMEN1TSHREPHX2AKR1C1 | |
| SCHEMBL30565520 | 0.84 | SLC6A4 (0.48) | KMT2AMEN1TSHREPHX2SLC6A4 | |
| SCHEMBL31169161 | 0.83 | EPHX2 (0.44) | KMT2AMEN1TSHREPHX2SLC6A4 | |
| SCHEMBL1374499 | 0.82 | APP (0.71) | AKR1C1APPAKR1C3AKR1C2CYP2C9 | |
| SCHEMBL4440466 | 0.82 | SLC6A4 (0.46) | EPHX2SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14894559 | 0.82 | SLC6A4 (0.41) | KMT2AMEN1TSHREPHX2SLC6A4 | |
| SCHEMBL27925689 | 0.81 | SLC6A4 (0.47) | EPHX2SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| EP-4486444-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-118871422-A | 3-Alkynyl carboxamides as AEP modulators | 豪夫迈·罗氏有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240217928-A1 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240217928-A1 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4377295-A1 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-06-05 | — | — | EP | disclosed |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2024-03-21 | — | — | US | disclosed |
| WO-2023165943-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| US-20080255192-A1 | 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008121817-A2 | QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION | WYETH (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008095821-A1 | INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080009524-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-10 | — | — | US | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | KMT2A 3156/4885MEN1 4355/4885TSHR 2080/4885 |
| US-20080009524-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | KMT2A 4313/4885MEN1 4687/4885TSHR 2748/4885 |
| US-20240217928-A1 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | NHERF1, ENPP1, ATP6AP1 | KMT2A 2938/4885MEN1 1657/4885TSHR 1268/4885 |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KMT2A 4313/4885MEN1 4687/4885TSHR 2748/4885 |
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | CNR2, CNR1, FAAH2 | KMT2A 1448/4885MEN1 4443/4885TSHR 636/4885 |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | KMT2A 4241/4885MEN1 4705/4885TSHR 2723/4885 |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | CFTR, ABCB4, ABCF2 | KMT2A 4080/4885MEN1 4624/4885TSHR 1747/4885 |
| US-20080255192-A1 | 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins | VCAM1, ICAM1, SELE | KMT2A 3971/4885MEN1 4659/4885TSHR 3701/4885 |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | CFTR, ABCD3, ABCC2 | KMT2A 3350/4885MEN1 4579/4885TSHR 2243/4885 |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | KMT2A 4575/4885MEN1 4331/4885TSHR 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.